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Abstract
The probiotic effects of Lactobacillus reuteri have been speculated to partly depend on its capacity to produce the
antimicrobial substance reuterin during the reduction of glycerol in the gut. In this study, the potential of this process to
protect human intestinal epithelial cells against infection with Salmonella enterica serovar Typhimurium was investigated.
We used a three-dimensional (3-D) organotypic model of human colonic epithelium that was previously validated and
applied to study interactions between S. Typhimurium and the intestinal epithelium that lead to enteric salmonellosis. Using
this model system, we show that L. reuteri protects the intestinal cells against the early stages of Salmonella infection and
that this effect is significantly increased when L. reuteri is stimulated to produce reuterin from glycerol. More specifically, the
reuterin-containing ferment of L. reuteri caused a reduction in Salmonella adherence and invasion (1 log unit), and
intracellular survival (2 log units). In contrast, the L. reuteri ferment without reuterin stimulated growth of the intracellular
Salmonella population with 1 log unit. The short-term exposure to reuterin or the reuterin-containing ferment had no
observed negative impact on intestinal epithelial cell health. However, long-term exposure (24 h) induced a complete loss
of cell-cell contact within the epithelial aggregates and compromised cell viability. Collectively, these results shed light on a
potential role for reuterin in inhibiting Salmonella-induced intestinal infections and may support the combined application
of glycerol and L. reuteri. While future in vitro and in vivo studies of reuterin on intestinal health should fine-tune our
understanding of the mechanistic effects, in particular in the presence of a complex gut microbiota, this the first report of a
reuterin effect on the enteric infection process in any mammalian cell type.
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Introduction
Intestinal infection by non-typhoidal Salmonella strains (NTS)
leads to gastroenteritis and diarrheal disease, and is a major source
of foodborne illness worldwide [1]. Salmonella enterica serovar
Typhimurium (S. Typhimurium) causes a self-limiting gastroen-
teritis and diarrheal disease in healthy individuals, but can cause
life threatening systemic illness in immuno-compromised individ-
uals. Usually, treatment relies on water and electrolyte supple-
mentation, but when the associated dehydration becomes severe
or when Salmonella reaches the bloodstream, antimicrobial
treatment becomes essential. However, since the 1990s multi-drug
resistant strains have emerged and are compounding the problems
associated with severe enteric salmonellosis [2,3]. Therefore, the
development of novel therapeutic treatments and vaccines is
ongoing. An alternative approach is to prevent or reduce Salmonella
infection, using benign microorganisms that are naturally occur-
ring in the gastrointestinal tract. The gut symbiont Lactobacillus
reuteri has previously been shown to protect against gastrointestinal
infections and even to reduce diarrhea in children [4,5]. However,
it remains unclear how these effects are mediated. In this study, we
explored the possibility for L. reuteri to decrease S. Typhimurium
infection of the intestinal epithelium by producing and excreting
the antimicrobial metabolite reuterin during the infection process.
Reuterin or the hydroxypropionaldehyde (HPA)-system is an
antimicrobial mixture of 3-HPA mono-, di- and polymers, and
HPA-hydrate. It is produced as an intermediate during the
reduction of glycerol to 1,3-propanediol (1,3-PDO) [6]. Several
gut bacterial species are described to produce reuterin in a
specialized bacterial compartment or metabolosome [7]. Among
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these species, L. reuteri is the one reported to most efficiently
produce reuterin and excrete relatively high amounts [8–10]. Only
recently, two studies demonstrated that reuterin’s mode of action
involves the modification of thiol groups in proteins and small
molecules, which results in oxidative stress and ultimately leads to
bacterial cell death [11,12]. Moreover, the latter studies indicated
that the aldehyde group in 3-HPA is the bioactive agent in
reuterin.
Several studies have investigated the antimicrobial activity of
reuterin by determining its minimal inhibitory and bactericidal
concentration (MIC and MBC) on pathogens and commensal gut
bacteria both in the absence and presence of L. reuteri [13–17].
Recent reports indicated that reuterin production also occurs in
mixed microbial communities found in human feces [18,19],
whereas Morita et al. [20] found in vivo reuterin production in the
caecum of gnotobiotic mice inoculated with L. reuteri. Furthermore,
there is increasing evidence that reuterin production is crucial for
the ecological behavior and probiotic properties of L. reuteri isolates
from the human gastrointestinal tract [21,22]. While mechanistic
in vitro studies demonstrated that L. reuteri may protect intestinal
cells against enteric infection by regulating immune responses [23–
27] or by competition for host binding sites [28], the effect of
reuterin production on modulating host-pathogen interactions
with eukaryotic cells has not yet been investigated. Hence, in this
study we assessed the capacity of reuterin to target the early stages
of S. Typhimurium interaction with human colonic epithelium
that lead to enteric salmonellosis, specifically adherence and
invasion, intracellular survival and intracellular growth (i.e.
colonization).
For these studies, we utilized a previously characterized rotating
wall vessel (RWV)-derived 3-D HT-29 organotypic model of
human intestinal epithelium. The application of a 3-D HT-29
model for this investigation is logical, since the former better
approximates the parental tissue and has been shown to be more
predictive of key in vivo responses to infection by S. Typhimurium
as compared to monolayers [29,30]. This is evidenced by 3-D HT-
29 cells exhibiting a) distinct apical and basolateral polarity, b)
enhanced expression and organization of tight junctions, extra-
cellular matrix, and brush border proteins, c) highly localized
mucus production, and d) differentiation into multiple epithelial
cell types relevant to those found in the intestine, including
enterocytes, goblet cells, Paneth cells and M-like cells [29–31].
These in vivo-like expression levels and distribution patterns of key
biological surface markers in 3-D cells are critical for differentiated
form and function. These traits of the 3-D models could contribute
to their ability to support pathogen infection in a manner more
akin to that in the infected host as compared to monolayers [31].
For example, the enhanced formation, integrity, and physiological
distribution of tight junctions in 3-D HT-29 epithelial cells could
serve as a protective barrier against pathogen invasion, thereby
reducing infection and maintaining structural integrity. In
addition, differences in mucus localization could alter bacterial
adherence and invasion into the underlying epithelium. Moreover,
the differentiation status of the intestinal epithelium drives
important differences in cytokine production in polarized cells
following bacterial infection as compared to their non-polarized
counterparts, which is also an important determinant of infection
outcome [32,33]. Likewise, the use of human surrogate infection
models that possess multiple epithelial cell types normally found in
the intestine is essential to better predict in vivo-like responses to
infection with enteric pathogens. When applied to study the early
stages of human enteric salmonellosis, the highly differentiated 3-
D HT-29 intestinal model responded in ways that were similar to
an in vivo infection, including differences in tissue morphology,
adherence, invasion, apoptosis and cytokine expression [29,31].
To our knowledge, 3-D HT-29 cells were the first in vitro model of
human intestinal epithelium to suggest that the Salmonella
Pathogenicity Island 1 Type Three Secretion System (SPI-1
T3SS) may not be the main determinant for invasion of Salmonella
into in vitro models of human intestinal epithelium [29].
Subsequent work demonstrated that all characterized S. Typhi-
murium T3SSs (SPI-1, SPI-2, and the flagellar pore) are
dispensable for Salmonella invasion into highly differentiated 3-D
HT-29 cells, but are required for intracellular bacterial growth,
paralleling in vivo infection observations and demonstrating the
utility of these models in predicting in vivo-like pathogenic
mechanisms and for studying host-microbe interactions [30].
Using this organotypic model, we show that glycerol conversion to
reuterin by L. reuteri reduces S. Typhimurium colonization of
human intestinal epithelium and might be a useful therapeutic
approach to consider for treatment and prevention of enteric
salmonellosis.
Methods
Bacterial Strains, Media and Growth Conditions
The strains used in this study are provided in Table 1. L. reuteri
ATCC PTA 6475 belongs to lineage II of the L. reuteri species [34].
The genome of lineage II L. reuteri contains the pdu-cbi-cob-hem gene
cluster, which encodes reuterin production [22]. A knock-out
mutant of pduC was generated using RecT-mediated oligonucle-
otide recombineering, as described by van Pijkeren and Britton
[35]. L. reuteri expressing RecT (strain RPRB0000) was used to
target the pduC gene (Genbank locus ZP_08162814; glycerol
dehydratase, large subunit) to yield strain RPRB1321, further
indicated as ATCC PTA 6475 DpduC. Mutations were verified by
PCR, and the integrity was confirmed by sequence analysis.
Oligonucleotides for recombineering and screening purposes are
available upon request.
S. Typhimurium and E. coli were grown on Lennox (L) agar
(Fisher, New Jersey, USA) and L. reuteri was grown on de Man-
Rogosa-Sharpe (MRS) agar (Difco, Maryland, USA) for 24 h at
37uC. Then, a colony of S. Typhimurium and E. coli was picked up
and grown overnight (for approximately 15 h) in 5 mL L broth at
37uC with shaking at 180 rpm. Prior to use in experiments,
overnight cultures were back-diluted 1:100 in L broth and grown
at 37uC with aeration until reaching mid-log phase of growth
(OD595 < 0.6). All infection studies were performed at a
multiplicity of infection (MOI) of approximately 1 bacterium per
host cell. Similarly, a colony of L. reuteri ATCC PTA and ATCC
PTA 6475 DpduC was picked and grown overnight (16–18 h) in
5 mL MRS broth either without or with 20 mM glycerol (99.9%,
Sigma, Missouri, USA) at 37uC with shaking at 180 rpm.
Ferments of ATCC PTA 6475 were prepared by harvesting
(1500 rcf for 10 min) and washing the pellets with 5 mL
Dulbecco’s Phosphate Buffered Saline (DPBS) with ions, and
incubating them in 5 mL of the mammalian cell culture medium
GTSF-2 without or with 100 mM glycerol during 2 h at 37uC
with shaking at 180 rpm. The supernatant of these ferments was
recovered after centrifugation at 8000 rcf for 10 min and filter-
sterilized over a 0.45 mM PVDF filter (Whatman, Maine, USA).
Prior to use in approach 1 experiments (Fig. 1), the supernatant
obtained by fermentation without glycerol was diluted 10-fold in
GTSF-2 medium (SN- 1:10) and the supernatant of the ferment
with glycerol was diluted 10-, 100- and 1000-fold, further
indicated as SN+1:10, SN+1:100 and SN+1:1000. For use in
approach 2 infection experiments (Fig. 1), ATCC PTA 6475 was
grown either in the absence or presence of 20 mM glycerol, while
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ATCC PTA 6475 DpduC was grown in the absence of glycerol.
Consecutively, the pellets were suspended in 5 mL GTSF-2
without (PTA 6475 -) or with 40 mM glycerol (PTA 6475+ and
PTA 6475 DpduC +). The L. reuteri cultures were diluted twice prior
to use in infection studies, resulting in a population of
(1.860.1)6109 CFU.mL21.
To our knowledge, there are no data available on actual
glycerol and reuterin concentrations in the human gut in vivo.
However, Morita et al. [20] were the first to demonstrate that
reuterin can be produced in vivo in the intestine of mice and that
feces of untreated mice contain glycerol concentrations of 7–
10 mM, suggesting the presence of glycerol in the intestine.
Moreover, glycerol may rapidly be consumed by the colon
microbiota [18,19], which indicates that actual glycerol concen-
trations in the intestine might be higher than those found in the
feces.
Reuterin Production and Quantification of Glycerol
Metabolites
Reuterin was produced by L. reuteri ATCC 53608 in a two-step
glycerol fermentation process and purified to a stock of 330 mM 3-
HPA as described previously [10]. Glycerol, acetic acid, lactic acid
and 1,3-PDO were quantified by means of HPLC-UV/RI.
Detailed information on sample preparation and analytical
parameters can be found in [19]. The concentration of 3-HPA
was determined in the fresh samples by means of a colorimetric
assay previously described by Vollenweider et al. [10] and modified
to a 96-well plate format by Spinler et al. [16]. In brief, 50 mL of a
(10-fold diluted) sample was mixed with 37.5 mL tryptophan
solution (0.01 M in 0.05 M HCl, stabilized with a few drops of
toluene per 250 mL) and 150 mL 12 M HCl, and incubated
during 20 min at 37uC. Then, reuterin was quantified as 3-HPA
based on the optical density measured at 550 nm and a standard
curve made with acrolein (Fluka, St. Louis, MO, USA).
Growth Inhibition of S. Typhimurium by 3-HPA and
Supernatants from the L. Reuteri Ferment
To assess the effects of the supernatants from the ATCC PTA
6475 ferment (SN- and SN+) and 3 mM 3-HPA on survival and
growth of S. Typhimurium, parallel experiments were performed
according to the approach 1 infection studies described below and
depicted in Fig. 1. The experiments were set-up in 24-well plates
(500 mL/well) in the absence of host cells and with a single
addition of the supernatants from the ATCC PTA 6475 ferment in
GTSF-2. Mid-log phase grown S. Typhimurium was added to the
wells at a concentration of 26106 cells.mL21 and incubated
statically at 37uC in a 5% CO2 environment. A 20-mL sample was
taken to plate 10-fold dilution series on L agar plates after 1, 4 and
24 h. The experiment was repeated three times and each time
performed in duplicate, resulting in two technical and three
biological replicates.
The minimal inhibitory concentrations (MICs) of 3-HPA and
the reuterin-containing supernatants of the ATCC PTA 6475
ferment were determined for S. Typhimurium x3339 using a
standard serial dilution overnight growth assay downscaled to a
96-well plate. In brief, 2-fold dilution series were made in GTSF-2
starting either from 33 mM 3-HPA (20 mL 3-HPA stock of
330 mM in milliQ +180 mL GTSF-2) or undiluted supernatant of
the ATCC PTA 6475 ferment. The final volume in each well was
100 mL. Then, a mid-log phase grown S. Typhimurium culture
was added to the wells in a maximum volume of 3.8 mL per well
and a final concentration of 26106 bacterial cells.mL21. The MIC
was determined to be an intermediate concentration lying between
that of the wells with and without visible growth (turbidity) after
24 h of static incubation at 37uC. The assay was repeated two
times from independent S. Typhimurium cultures, each including
3 replicates.
3-D Model of Colonic Epithelium
Three-dimensional intestinal models were derived from the
human colonic epithelial cell line HT-29 (American Type Culture
Collection ATCC # HTB-38), using the RWV bioreactor from
Synthecon as previously described [29,30]. For all studies, HT-29
cells were cultured in GTSF-2 medium (Hyclone) supplemented
with heat-inactivated fetal bovine serum (Invitrogen, California,
USA), ITS (insulin-transferrin-sodium selenite; Sigma, Missouri,
USA), sodium bicarbonate, penicillin/streptomycin (Sigma, Mis-
souri, USA) and fungizone (Invitrogen, California, USA) as
described by Bentrup et al. [29]. Fresh medium was replenished
after 5 days and then every 24 h until harvest of the cultures after
15–18 days.
Adherence and Invasion, Intracellular Survival and
Intracellular Growth Assays
A gentamicin exclusion assay was performed to assess
S. Typhimurium adhesion and invasion (1 h), intracellular survival
(4 h) and intracellular growth (24 h). The experimental flow was
modified from previous publications [29,30,36] and is depicted in
Fig. 1. Two days prior to the infection experiments, 3-D HT-29
cells were grown in antibiotic free GTSF-2, and streak incubations
of the bacterial cultures were started on agar and further prepared
as described above. On the day of infection (day 15–18), the 3-D
aggregates were removed from the RWV bioreactor and seeded
evenly into 48-well plates with 26106 cells.mL21 and 250 mL
GTSF-2 per well. The number of cells associated with 3-D
aggregates was determined by dissociation into individual cells
Table 1. Overview of the bacterial strains used in this study.
Bacterial strains Description Source
Salmonella enterica serovar Typhimurium x3339 Animal-passaged isolate of the virulent SL1344 wild-type strain [65]
Escherichia coli HB101 Non-invasive extracellular [66]
L. reuteri ATCC PTA 6475 Isolate from Finnish mother’s milk BioGaia AB
(Raleigh, USA)
RPRB0000 L. reuteri expressing RecT [35]
RPRB1321– ATCC PTA 6475 DpduC L. reuteri::oJP859 (pduC": W24X, P25I, E26Q)
pduC knockout, unable to produce glycerol dehydratase
This study
": pduC: HMPREF0536_1321. Resultant amino acid changes after incorporation of the oligonucleotide are listed after each gene, and X represents a stop codon.
doi:10.1371/journal.pone.0037116.t001
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with 0.25% trypsin-EDTA. The cell number and viability were
determined by 0.4% trypan blue (1:1) (Sigma, Missouri, USA) dye
exclusion and counting in a hemocytometer. S. Typhimurium or
non-invasive E. coli were added to the 3-D HT-29 cells at an MOI
of approximately 1-to-1 (bacteria-to-host cell). In approach 1
infection experiments, 3-D aggregates were exposed to S. Typhi-
murium or E. coli together with (a) 3-HPA (3 mM) or (b) dilutions
of the supernatants from the L. reuteri ferment as described above.
Infections according to approach 2 were done in the presence of
an established (reuterin-producing) L. reuteri population. Non-
exposed controls (with and without bacteria) were included. Both
approach 1 and 2 cultures were incubated for 1 h in a 5% CO2
environment at 37uC, yielding adhered and invaded S. Typhimur-
ium. Medium was subsequently changed to GTSF-2 containing
gentamicin to eliminate extracellular bacteria, and cells were
incubated for an additional 3 h. Then, the intracellular bacteria
were determined (survival) and again fresh medium with
gentamicin was added for a final incubation until 24 h after the
start of infection to determine intracellular growth. At each time
point, adherent and/or intracellular bacteria were quantified after
lysing the host cells with 0.1% sodium deoxycholate (approach 1)
or 1% triton (approach 2) and plating serial dilutions of the lysates
on L agar plates overnight. Additionally, host cell viability was
assessed following trypsinization of the 3-D aggregates, staining
with 0.4% trypan blue (1:1) (Sigma, Missouri, USA) and counting
in a hemocytometer. All infection experiments were performed at
least twice, in duplicates, resulting in a minimum of two technical
and two biological replicates.
Statistical Analysis
Significant differences between treatments were detected with
SPSS Statistics 19. Normality was tested with the Kolmogorov-
Smirnoff test. Normal distributed data were analyzed using one-
way ANOVA, testing for equality of the variances with the
Modified Levene test and determining the p-value according to
Bonferroni or Dunnett T3. Significant differences within non-
normal distributions were detected using the Mann-Whitney U
test. The significance level was set at 0.05.
Results
Characterization of the Supernatants from the L. Reuteri
Ferment
A fully-grown culture of L. reuteri ATCC PTA 6475 was
incubated in GTSF-2 without (SN-) and with 100 mM glycerol
(SN+) for 2 h. The supernatant of these ferments was character-
ized for its glycerol, 3-HPA, 1,3-PDO, acetic acid and lactic acid
content (Table 2). Prior to application in growth and infection
experiments the SN- supernatant was diluted 10-fold and the SN+
supernatant 10-, 100- or 1000-fold. In the SN+ supernatant,
6764 mol % of the supplemented glycerol had been converted to
3-HPA (6267% of converted glycerol) and 1,3-PDO (4266% of
converted glycerol). Acetic acid and lactic acid were formed in
both the SN- and the SN+ supernatant, but in different amounts.
The lactic acid concentration was significantly higher in the SN-
supernatants (p,0.001), while the acetic acid concentration was
more than 3-fold higher in the SN+ supernatants (p,0.001). The
pH of all dilutions was very similar with an average value of
7.4960.02.
Growth Effects of Supernatants from the L. Reuteri
Ferment and Pure 3-HPA on a S. Typhimurium
Population
The growth effects of the supernatant from the L. reuteri ferments
on the S. Typhimurium population were assessed after 1, 4 and
24 h of exposure to dilutions of the ferment, parallel to the
approach 1 infection assay. Fig. 2 shows the reduction of the
x3339 population after exposure to the 10-fold diluted reuterin-
containing supernatant (SN+1:10, 2.560.4 mM 3-HPA) with
0.260.1 (1 h), 1.860.1 (4 h) and 6.560.7 (24 h) log units,
respectively. Addition of 3 mM 3-HPA resulted in a similar
reduction of the x3339 population (0.160.1, 1.760.1 and 7.060.6
for 1, 4 and 24 h, respectively). No significant growth effects were
observed for higher dilutions of the same supernatant (SN+1:100
and SN+1:1000) or the supernatant without reuterin (SN- 1:10).
The MIC-value of the supernatants from the reuterin-contain-
ing ferment of L. reuteri corresponded to a 3-HPA concentration
between 0.9 and 1.4 mM, as calculated from the MIC-values
obtained for two biological replicates. The MIC-value of pure 3-
HPA was found to lie between 1.0 and 2.1 mM.
Infection of 3-D Intestinal Cells with S. Typhimurium in
the Presence of Supernatants from the L. Reuteri Ferment
or Pure 3-HPA (Approach 1)
After assessment of the growth effects of the L. reuteri
supernatant and pure 3-HPA on S. Typhimurium x3339, their
capacity to generate similar effects in the presence of eukaryotic
cells and to protect the intestinal epithelium against S. Typhimur-
ium infection was tested. This approach allowed us to more closely
assess the effect of reuterin on the in vivo infection process of
S. Typhimurium. Therefore, 3-D HT-29 cells infected with
S. Typhimurium were exposed to L. reuteri supernatant and pure
3-HPA under the same conditions of incubation (medium,
temperature, CFU.mL21, 3-HPA concentration) as for the
experiments with S. Typhimurium in the absence of host cells.
The 10-fold diluted reuterin-containing supernatant
(2.560.4 mM 3-HPA) from the L. reuteri ferment was able to
significantly reduce x3339 adhesion and invasion, and intracellu-
Figure 1. Experimental procedure for infection of 3-D HT-29 aggregates with S. Typhimurium x3339 (red line). Approach 1 infection
experiments were done in the presence of supernatants of the L. reuteri ferment with or without reuterin (green star), while approach 2 infections
were done in the presence of an established L. reuteri population (blue line) producing reuterin in situ.
doi:10.1371/journal.pone.0037116.g001
Table 2. Quantification of the glycerol, 3-
hydroxypropionaldehyde (3-HPA), 1,3-propanediol (1,3-PDO),
acetic acid and lactic acid contents (mM) in the supernatant of
the L. reuteri ferments without (SN-) or supplemented with
100 mM glycerol (SN+).
mM
L. reuteri ferment no
Glycerol (SN-)
L. reuteri ferment
+100 mM glycerol
(SN+)
Glycerol bdl 32.863.6
3-HPA bdl 24.564.0
1,3-PDO bdl 38.763.2
acetic acid 4.060.6 13.660.5
lactic acid 13.360.5 9.760.4
bdl: below detection limit (1.1 mM for glycerol; 0.8 mM for 3-HPA and 1.3 mM
1,3-PDO).
doi:10.1371/journal.pone.0037116.t002
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lar survival with 0.760.2 and 1.660.3 log units, respectively,
when compared to the untreated S. Typhimurium control (Fig. 3).
Moreover, after 24 h no x3339 survival was detected (detection
limit = 102 CFU.mL21). Higher dilutions of the reuterin-contain-
ing supernatants did not result in any statistically significant
differences compared to the control (Fig. 3). Addition of 3 mM 3-
HPA resulted in a 0.860.1 log unit reduction of the x3339
intracellular survival (Fig. 3). However, it did not affect x3339
adhesion and invasion. Interestingly, the 10-fold diluted L. reuteri
supernatant without reuterin was found to stimulate x3339
adhesion and invasion, and intracellular survival, with a 0.760.2
log unit increase in intracellular growth after 24 h (Fig. 3).
In Fig. 4, the effects of 3 mM 3-HPA and the supernatants of
the L. reuteri ferments on x3339 adhesion and invasion, intracel-
lular survival and growth are compared with those found when no
HT-29 aggregates were added (Fig. 2). In the presence of the HT-
29 aggregates, both supernatants seemed to affect the x3339
population stronger. For the reuterin-containing supernatant
(SN+1:10; 2.5 mM 3-HPA) and 3 mM pure 3-HPA, a bacterio-
static effect was observed up to 4 h of exposure in the absence of
the HT-29 aggregates, while in the presence of these aggregates,
the reuterin-containing supernatant – but not pure 3-HPA –
immediately affected the x3339 population viability after 1 h. In
addition, the supernatants without reuterin (SN- 1:10) significantly
stimulated x3339 intracellular growth in the presence of HT-29
aggregates, while no such effect was observed for the SN- 1:10
supernatant in the absence of the aggregates.
The negative control strain, Escherichia coli HB101, did not
exhibit invasion into the colon cells, as no bacterial colony forming
units were detected after addition of gentamicin to the medium
(4 h) (detection limit = 102 CFU.mL21).
Infection of 3-D Intestinal Cells with S. Typhimurium in
the Presence of an Established L. Reuteri Population
(Approach 2)
The importance of glycerol reduction and reuterin production
for L. reuteri to protect against x3339 infection was tested in an
approach 2 gentamicin exclusion assay (Fig. 1). An overnight
culture of wild-type L. reuteri ATCC PTA 6475 was suspended in
fresh GTSF-2 medium supplemented with 40 mM glycerol and
incubated in the presence of 3-D HT-29 cells to allow for in situ
reuterin production. The average reuterin production was
2.861.0 mM (after 30 min) and 3.861.3 mM (after 1 h30).
Negative controls were provided by incubating (1) a pduC knockout
of ATCC PTA 6475 in GTSF-2 with 40 mM glycerol and (2)
ATCC PTA 6475 in GTSF-2 without glycerol. Reuterin
production by both negative controls was always below detection
Figure 2. 3-HPA and the 10-fold diluted reuterin-containing supernatant significantly decreased the S. Typhimurium x3339
population. Log difference in x3339 counts (CFU.mL21) of the untreated x3339 control minus the treatments with 3 mM 3-HPA, the 10-, 100- or
1000-fold diluted supernatants containing reuterin (respectively SN+1:10 with 2.5 mM 3-HPA, SN+1:100; 0.25 mM 3-HPA and SN+1:1000; 0.025 mM 3-
HPA) and the 10-fold diluted supernatant without reuterin (SN- 1:10) after 1, 4 and 24 h of exposure. Significant differences between the treatments
are indicated with different letters (a or b; p,0.05).
doi:10.1371/journal.pone.0037116.g002
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Figure 3. The 10-fold diluted reuterin-containing supernatant decreased S. Typhimurium x3339 colonization in 3-D HT-29
aggregates, while the supernatant without reuterin stimulated x3339 intracellular survival and growth. Log difference in x3339 counts
(CFU.mL21) of the untreated x3339 control minus the treatments with 3 mM 3-HPA, the 10-, 100- and 1000-fold diluted supernatants containing
reuterin (respectively SN+1:10 with 2.5 mM 3-HPA, SN+1:100; 0.25 mM 3-HPA and SN+1:1000; 0.025 mM 3-HPA) and the 10-fold diluted supernatant
without reuterin (SN- 1:10) after 1 h (adhesion & invasion), 4 h (intracellular survival) and 24 h (intracellular growth) of exposure. The non-invasive
E. coli HB101 control strain did not show countable colonies at the lowest dilution (detection limit = 102 CFU.mL21). Significant differences between
the treatments are indicated with different letters (a, b, c or d; p,0.05). bdl=below detection limit.
doi:10.1371/journal.pone.0037116.g003
Figure 4. The L. reuteri supernatants affected the S. Typhimurium x3339 population stronger in the presence of the 3-D HT-29
aggregates. Log counts (CFU.mL21) of the x3339 population (initial inoculum 26106 cells.mL21) exposed to the 10-fold diluted supernatant without
(SN- 1:10) and with reuterin (SN+1:10, 2.5 mM 3-HPA) both in the absence (left) and presence (right) of 3-D HT-29 aggregates. Detection
limit = 102 CFU.mL21.
doi:10.1371/journal.pone.0037116.g004
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limit (0.8 mM for 3-HPA). Fig. 5A shows that the presence of both
wild type and pduC knockout strains of L. reuteri ATCC PTA 6475
significantly reduced x3339 adhesion and invasion, but that this
reduction was significantly higher when reuterin was produced in
situ. Interestingly, the presence of all L. reuteri strains during the first
1 h30 of the assay further reduced the relative survival of the
invaded x3339 population after 4 h (Fig. 5B), but stimulated
x3339 intracellular growth after 24 h (Fig. 5C) when compared to
the Salmonella control. For these time points, no significant
differences were observed between reuterin-producing L. reuteri
populations and the negative L. reuteri controls.
3-D HT-29 Aggregate Morphology and Cell Viability
For every time point of the infection assays, separate wells were
used to assess morphology of the 3-D HT-29 aggregates under a
light microscope and to quantify cell viability after trypsinization
and trypan blue staining. For both approaches 1 and 2 infection
assays, a maximum of 10% dead cells was found for the aggregates
exposed to all conditions after 1 and 4 h, both in the presence and
absence of S. Typhimurium. An example for the morphology of
these healthy aggregates is depicted in Fig. 6A. However, after
24 h a remarkable difference was observed in the morphology of
aggregates exposed to 3 mM 3-HPA and the reuterin-containing
L. reuteri supernatant (SN+1:10, 2.560.4 mM 3-HPA), when
compared to the other treatments and controls. Fig. 6B depicts
the complete destruction of the 3-D structure of the aggregates
into that of a single cell suspension. Moreover, 55620% of these
single cells were dead, as indicated by their absorption of trypan
blue (Fig. 6C). Exposure to all other treatments of both approaches
1 and 2, and the untreated S. Typhimurium controls did not lead
to any significant effect on cell viability at the 24 h exposure time
point and resulted in 3-D morphology comparable to that shown
in Fig. 6A.
Discussion
Due to the increasing incidence of multidrug-resistant and
highly invasive Salmonella strains, the development of new
therapeutic treatments against human enteric salmonellosis
becomes critical. In this study, we demonstrated the capacity of
the reuterin-containing glycerol ferment of the probiotic and
commensal species L. reuteri to significantly decrease adhesion and
invasion, and intracellular survival of S. Typhimurium in a 3-D
organotypic model of colonic epithelium. Moreover, it was found
that an established L. reuteri population had an additional
protective effect against x3339 adhesion and invasion when it
was able to convert glycerol to reuterin in situ. In contrast to
conventional 2-D monolayers, our 3-D colon model was
previously shown to respond to S. Typhimurium infection in key
ways that reflect the infection process in vivo, including adherence,
invasion, structural damage, cytokine production, and the lack of
dependence on the SPI-1, SPI-2 and flagellar T3SS for Salmonella
invasion [29,30]. These findings highlight the relevance of our
organotypic models for use as novel platforms to provide unique
insight for development and screening of new therapies against
Salmonella infection.
In approach 1 infection experiments, we compared the potential
of the ferment of L. reuteri without and with glycerol to decrease
colonization of the 3-D model colon epithelium by an actively
growing x3339 population (Fig. 3). Only the glycerol-supplement-
ed ferment that contained reuterin at concentrations of
2.560.4 mM 3-HPA was found to significantly decrease coloni-
zation by x3339. Higher dilutions of the reuterin-containing
glycerol ferment (containing 0.2560.04 mM 3-HPA and
0.02560.004 mM 3-HPA) did not change the x3339 infection
process. However, the ferment without glycerol actually stimulated
x3339 intracellular survival and growth significantly. In this
respect, the low concentrations of 3-HPA in the diluted reuterin-
containing ferments (0.2560.04 mM and 0.02560.004 mM)
Figure 5. The presence of an established L. reuteri population reduced x3339 adhesion and invasion in 3-D HT-29 aggregates, and
this effect was significantly higher when L. reuteri was producing reuterin in situ. Log differences in x3339 counts (CFU.mL21) of (A)
adhered and invaded minus initial inoculum, (B) intracellular surviving minus adhered and invaded, and (C) intracellular growth minus survival upon
exposure to an established population of L. reuteri ATCC PTA 6475 producing reuterin (PTA 6475+40 mM gly) or unable to produce reuterin (DpduC
+40 mM gly and PTA 6475 no gly). Significant differences between the treatments are indicated with different letters (a, b or c; p,0.05).
doi:10.1371/journal.pone.0037116.g005
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could have counteracted the stimulatory effect on x3339
intracellular survival and growth, as was observed for the ferment
without glycerol or reuterin. This stimulatory effect might have
been caused by the presence of low concentrations of acetic acid.
This bacterial product was previously shown to stimulate the
expression of SPI-1 T3SS genes at pH 6.7 but not at pH 8.0
[37,38]. Since, the pH in our study was approximately 7.5, other
unknown mechanisms were possibly involved in this stimulatory
effect. Overall, these data illustrate the importance of glycerol and
its conversion to reuterin for the inhibitory effects of the L. reuteri
ferment towards x3339 colonization.
Interestingly, the effects of pure 3-HPA and the L. reuteri ferment
(both with and without glycerol) on the x3339 population infecting
host cells were found to be more profound than those in the
absence of host cells (Fig. 4). Moreover, in the presence of the 3-D
HT-29 cultures, pure 3-HPA exhibited a reduced ability to affect
adherence and invasion, and intracellular survival of x3339
populations as compared to the L. reuteri supernatant containing a
similar amount of 3-HPA (2.560.4 mM 3-HPA). Interestingly, in
the absence of host cells, both treatments resulted in an equal
decrease of the x3339 population. This suggests that the
(combined) effect of L. reuteri metabolites on the ability of
S. Typhimurium to colonize our well-differentiated models of
intestinal epithelium may be enhanced due to (1) an increased
sensitivity of x3339 to these compounds in the context of an
epithelial infection and/or (2) a host response to the bacterial
metabolites of L. reuteri that affects the x3339 infection process.
The first mechanism could involve a direct or indirect effect of
reuterin (alone or together with other metabolites) on Salmonella
genes or their products that mediate colonization of the intestinal
epithelium. While extremely limited information is available
regarding the effect of reuterin on the mechanisms of Salmonella
enteric pathogenesis, Kim et al. [39] found that a low concentra-
tion of reuterin (0.26 mM) is able to effectuate a moderate and
short-term down-regulation of the SPI-1 T3SS genes invA and hilA
without affecting the survival or growth of the S. Typhimurium
culture after 8 h of exposure. The SPI-1 T3SS has been shown to
be essential for Salmonella invasion into a variety of model host
systems [33,40–46]. However, the choice of host species alters
Salmonella infection strategies, and it was previously shown that the
SPI-1 T3SS is not required for S. Typhimurium invasion into our
highly differentiated 3-D HT-29 colon models [29,30], which is in
agreement with studies reporting that SPI-1 is not required to
cause enteropathogenesis in vivo [47–52]. Given the growing
interest in the use of probiotics to maintain intestinal homeostasis
and their potential to protect against enteric infection, identifica-
tion of the mechanism(s) by which reuterin impacts intestinal
colonization by Salmonella will likely become an area of expanding
investigation. Central to the successful identification of these
mechanisms will be the use of advanced intestinal models like
those used in this study that exhibit key similarities to the responses
of their in vivo parental tissues during a Salmonella infection.
Figure 6. Long-term (24 h) exposure of 3-D HT-29 aggregates to 3-HPA (2.5–3 mM) results in loss of cell-cell contact and cell
viability. (A) Aggregates of HT-29 colon cancer cells grown in three dimensions on porous collagen-coated microcarrier beads. The picture
represents the situation for all treatments after 0, 1 and 4 h and the treatments with the L. reuteri supernatants without reuterin (SN- 1:10) or
containing low concentrations of reuterin (SN+1:100 with 0.25 mM 3-HPA and SN+1:1000 with 0.025 mM 3-HPA) after 24 h. (B) Example of a single
cell suspension and naked porous collagen-coated microcarrier beads after 24 h of exposure to 3 mM 3-HPA or the 10-fold diluted reuterin-
containing L. reuteri supernatant (SN+1:10, 2.5 mM 3-HPA). (C) Example of live/dead counts of trypan blue treated single cell suspensions depicted in
B with a hemocytometer. Dead cells are colored blue.
doi:10.1371/journal.pone.0037116.g006
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The second mechanism would require the direct interaction of
reuterin with the host cells, as 3-HPA was previously shown to
bind to thiol groups and glutathione [11,12]. In addition, reuterin
can be spontaneously dehydrated to acrolein, which is a highly
reactive toxin with a mutagenic potency comparable to that of
formaldehyde [53,54]. A possible reuterin interaction with host
cells was furthermore supported in our study by the destruction of
the 3-D aggregate structure and loss of cell viability within 24 h of
exposure to both 3 mM pure 3-HPA and the reuterin-containing
L. reuteri ferment (2.560.4 mM 3-HPA) (Fig. 6). This is the first
study showing a reuterin effect on a model of intestinal epithelium.
However, many in vivo trials support the safe administration of
high doses of L. reuteri strains to full-term healthy infants younger
than 4 months, healthy and even HIV-infected adults [55–58].
Given the reactive nature of reuterin with microbes and proteins,
it could therefore be proposed that, in vivo, colonic reuterin
interacts first with the luminal bacteria and bacteria colonizing the
outer layer of the mucosal interface of the intestinal epithelium
[59,60], before it would affect the host. Further in vitro studies
should carefully determine whether our observed reuterin effects
are relevant in the presence of a complex gut microbiota and to
what extent glycerol can be safely supplemented as a nutrient for
the basal or enriched L. reuteri population in the human gut.
To further validate the safety and importance of the glycerol
metabolism for L. reuteri to protect against intestinal S. Typhimur-
ium infection, a second series of experiments was performed in
which the model colon epithelium was infected with x3339 in the
presence of an established L. reuteri population that was either
unable or stimulated to produce reuterin from glycerol (Fig. 5). In
either case, L. reuteri was able to significantly reduce S. Typhimur-
ium adhesion and invasion. This result was expected, as several
research groups have demonstrated the capacity of L. reuteri to
protect intestinal epithelial cells against inflammation and enteric
infection by regulating the expression of pro- and anti-inflamma-
tory cytokines [23–27] or to decrease S. Typhimurium adherence
to Caco-2 cells [28]. However, we found that L. reuteri populations
that were stimulated to convert glycerol to reuterin caused a
significantly higher reduction of x3339 adhesion and invasion as
compared to populations that were not able to produce reuterin.
Hence, in addition to L. reuteri’s protective effects via immunoreg-
ulatory modulation or competition for binding places [23–28], our
results indicate that protection against S. Typhimurium could also
occur via its capacity to produce reuterin from glycerol. This
process was recently found to be important for the success and
ecological behavior of L. reuteri strains isolated from the human
gastrointestinal tract (GIT), poultry and to a lesser extent from pigs
[21]. Moreover, glycerol is a potential nutrient source for
Salmonella [61] and the latter was suggested to have acquired part
of the genomic island for reuterin production via horizontal gene
transfer, indicating that L. reuteri and Salmonella are potential
competitors for the glycerol niche [20,62]. Increasingly, metabolic
pathways of the host and its associated microbiome are indicated
to support growth of S. Typhimurium [63]. However, in this study
we found an inhibitory microbial pathway that requires the
presence of glycerol and L. reuteri. Previous studies indicated that
the production of propionate and butyrate by the colon
microbiota, but not acetate, reduces Salmonella invasion in the
large intestine of mice [37,38]. Together, these data suggest that
management of the gut microbial metabolism towards such
inhibitory pathways may be a new tool to protect against or treat
Salmonella infections [38].
In conclusion, our results suggest that glycerol conversion to
reuterin by L. reuteri might be an effective therapeutic approach to
consider for protection against and treatment of intestinal
Salmonella infections. However, prior to investigating its use as a
potential antimicrobial agent in humans, both in vitro colonic
fermentation studies [64] and in vivo model studies with reuterin
would need to be performed to determine the effects and
mechanisms of this compound on gastrointestinal health.
Acknowledgments
The authors like to thank Tim Lacoere for designing the overview figure of
the experimental set-up (Fig.1).
Author Contributions
Conceived and designed the experiments: RDW AC CAN TVdW.
Performed the experiments: RDW AC SS. Analyzed the data: RDW AC
CAN. Contributed reagents/materials/analysis tools: SR SV CL JPvP RB.
Wrote the paper: RDW AC CAN SR CL TVdW.
References
1. WHO (2005) Drug-resistant Salmonella. Department FS, editor. Fact sheet Nu
139.
2. Chiu LH, Chiu CH, Horn YM, Chiou CS, Lee CY, et al. (2010)
Characterization of 13 multi-drug resistant Salmonella serovars from different
broiler chickens associated with those of human isolates. BMC Microbiology 10:
10.
3. Wiesner M, Calva E, Fernandez-Mora M, Cevallos MA, Campos F, et al. (2011)
Salmonella Typhimurium ST213 is associated with two types of IncA/C plasmids
carrying multiple resistance determinants. BMC Microbiology 11: 11.
4. Casas IA, Dobrogosz WJ (2000) Validation of the probiotic concept: Lactobacillus
reuteri confers broad-spectrum protection against disease in humans and animals.
Microbial Ecology in Health and Disease 12: 247–285.
5. Weizman Z, Asli G, Alsheikh A (2005) Effect of a probiotic infant formula on
infections in child care centers: Comparison of two probiotic agents. Pediatrics
115: 5–9.
6. Vollenweider S, Lacroix C (2004) 3-Hydroxypropionaldehyde: applications and
perspectives of biotechnological production. Applied Microbiology and
Biotechnology 64: 16–27.
7. Sriramulu DD, Liang M, Hernandez-Romero D, Raux-Deery E, Lunsdorf H, et
al. (2008) Lactobacillus reuteri DSM 20016 produces cobalamin-dependent diol
dehydratase in metabolosomes and metabolizes 1,2-propanediol by dispropor-
tionation. Journal of Bacteriology 190: 4559–4567.
8. Talarico TL, Casas IA, Chung TC, Dobrogosz WJ (1988) Production and
isolation of reuterin, a growth inhibitor produced by Lactobacillus reuteri.
Antimicrobial Agents and Chemotherapy 32: 1854–1858.
9. Luthi-Peng Q, Scharer S, Puhan Z (2002) Production and stability of 3-
hydroxypropionaldehyde in Lactobacillus reuteri. Applied Microbiology and
Biotechnology 60: 73–80.
10. Vollenweider S, Grassi G, Konig I, Puhan Z (2003) Purification and structural
characterization of 3-hydroxypropionaldehyde and its derivatives. Journal of
Agricultural and Food Chemistry 51: 3287–3293.
11. Schaefer L, Auchtung TA, Hermans KE, Whitehead D, Borhan B, et al. (2010)
The antimicrobial compound reuterin (3-hydroxypropionaldehyde) induces
oxidative stress via interaction with thiol groups. Microbiology-SGM 156:
1589–1599.
12. Vollenweider S, Evers S, Zurbriggen K, Lacroix C (2010) Unraveling the
hydroxypropionaldehyde (HPA) system: an active antimicrobial agent against
human pathogens. Journal of Agricultural and Food Chemistry 58:
10315–10322.
13. Axelsson LT, Chung TC, Dobrogosz WJ, Lindgren SE (1989) Production of a
broad-spectrum antimicrobial substance by Lactobacillus reuteri. Microbial Ecology
in Health and Disease 2: 131–136.
14. Arques JL, Fernandez J, Gaya P, Nunez M, Rodriguez E, et al. (2004)
Antimicrobial activity of reuterin in combination with nisin against food-borne
pathogens. International Journal of Food Microbiology 95: 225–229.
15. Cleusix V, Lacroix C, Vollenweider S, Duboux M, Le Blay G (2007) Inhibitory
activity spectrum of reuterin produced by Lactobacillus reuteri against intestinal
bacteria. BMC Microbiology 7: 9.
16. Spinler JK, Taweechotipatr M, Rognerud CL, Ou CN, Tumwasorn S, et al.
(2008) Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial
activities targeting diverse enteric bacterial pathogens. Anaerobe 14: 166–171.
17. Bian L, Molan AL, Maddox I, Shu QA (2010) Antimicrobial activity of
Lactobacillus reuteri DPC16 supernatants against selected food borne pathogens.
World Journal of Microbiology & Biotechnology 27: 991–998.
18. Cleusix V, Lacroix C, Vollenweider S, Le Blay G (2008) Glycerol induces
reuterin production and decreases Escherichia coli population in an in vitro model
Reuterin Protects against S. Typhimurium Infection
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e37116
of colonic fermentation with immobilized human feces. FEMS Microbiology
Ecology 63: 56–64.
19. De Weirdt R, Possemiers S, Vermeulen G, Moerdijk-Poortvliet TCW,
Boschker HTS, et al. (2010) Human faecal microbiota display variable patterns
of glycerol metabolism. FEMS Microbiology Ecology 74: 601–611.
20. Morita H, Toh H, Fukuda S, Horikawa H, Oshima K, et al. (2008) Comparative
genome analysis of Lactobacillus reuteri and Lactobacillus fermentum reveal a genomic
island for reuterin and cobalamin production. DNA Research 15: 151–161.
21. Walter J, Britton RA, Roos S (2011) Host-microbial symbiosis in the vertebrate
gastrointestinal tract and the Lactobacillus reuteri paradigm. Proceedings of the
National Academy of Sciences of the United States of America 108: 4645–4652.
22. Frese SA, Benson AK, Tannock GW, Loach DM, Kim J, et al. (2011) The
evolution of host specialization in the vertebrate gut symbiont Lactobacillus reuteri.
PLoS Genetics 7: 16.
23. Maassen CBM, van Holten-Neelen C, Balk F, den Bak-Glashouwer JH, Leer RJ,
et al. (2000) Strain-dependent induction of cytokine profiles in the gut by orally
administered Lactobacillus strains. Vaccine 18: 2613–2623.
24. Peran L, Sierra S, Comalada M, Lara-Villoslada F, Bailon E, et al. (2007) A
comparative study of the preventative effects exerted by two probiotics,
Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid
model of rat colitis. British Journal of Nutrition 97: 96–103.
25. Lin YP, Thibodeaux CH, Pena JA, Ferry GD, Versalovic J (2008) Probiotic
Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflammatory
Bowel Diseases 14: 1068–1083.
26. Liu YY, Fatheree NY, Mangalat N, Rhoads JM (2010) Human-derived
probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation.
American Journal of Physiology-Gastrointestinal and Liver Physiology 299:
G1087–G1096.
27. Jones SE, Versalovic J (2009) Probiotic Lactobacillus reuteri biofilms produce
antimicrobial and anti-inflammatory factors. BMC Microbiology 9: 9.
28. Todoriki K, Mukai T, Sato S, Toba T (2001) Inhibition of adhesion of food-
borne pathogens to Caco-2 cells by Lactobacillus strains. Journal of Applied
Microbiology 91: 154–159.
29. Bentrup KHZ, Ramamurthy R, Ott CM, Emami K, Nelman-Gonzalez M, et al.
(2006) Three-dimensional organotypic models of human colonic epithelium to
study the early stages of enteric salmonellosis. Microbes and Infection 8:
1813–1825.
30. Radtke AL, Wilson JW, Sarker S, Nickerson CA (2010) Analysis of interactions
of Salmonella Type Three Secretion mutants with 3-D intestinal epithelial cells.
PLoS One 5: 12.
31. Barrila J, Radtke AL, Crabbe A, Sarker SF, Herbst-Kralovetz MM, et al. (2010)
Organotypic 3-D cell culture models: using the rotating wall vessel to study host-
pathogen interactions. Nature Reviews Microbiology 8: 791–801.
32. Hobert ME, Sands KA, Mrsny RJ, Madara JL (2002) Cdc42 and Rac1 regulate
late events in Salmonella Typhimurium-induced interleukin-8 secretion from
polarized epithelial cells. Journal of Biological Chemistry 277: 51025–51032.
33. Hurley BP, McCormick BA (2003) Translating tissue culture results into animal
models: the case of Salmonella Typhimurium. Trends in Microbiology 11:
562–569.
34. Oh PL, Benson AK, Peterson DA, Patil PB, Moriyama EN, et al. (2010)
Diversification of the gut symbiont Lactobacillus reuteri as a result of host-driven
evolution. ISME Journal 4: 377–387.
35. van Pijkeren J, Britton R (2012) High-efficiency recombineering in lactic acid
bacteria. Nucleic Acids Research. In press DOI: 10.1093/nar/GKS147.
36. Nickerson CA, Goodwin TJ, Terlonge J, Ott CM, Buchanan KL, et al. (2001)
Three-dimensional tissue assemblies: Novel models for the study of Salmonella
enterica serovar Typhimurium pathogenesis. Infection and Immunity 69:
7106–7120.
37. Lawhon SD, Maurer R, Suyemoto M, Altier C (2002) Intestinal short-chain fatty
acids alter Salmonella Typhimurium invasion gene expression and virulence
through BarA/SirA. Molecular Microbiology 46: 1451–1464.
38. Van Immerseel F, Russell JB, Flythe MD, Gantois I, Timbermont L, et al. (2006)
The use of organic acids to combat Salmonella in poultry: a mechanistic
explanation of the efficacy. Avian Pathology 35: 182–188.
39. Kim JY, Ryu S, Ji GE (2007) Effects of sulforaphane, grapefruit seed extracts,
and reuterin on virulence gene expression using hilA and invF fusion strains of
Salmonella Typhimurium. Food Science and Biotechnology 16: 778–782.
40. Pullinger GD, Paulin SM, Charleston B, Watson PR, Bowen AJ, et al. (2007)
Systemic translocation of Salmonella enterica serovar Dublin in cattle occurs
predominantly via efferent lymphatics in a cell-free niche and requires type III
secretion system I (T3SS-1) but not T3SS-2. Infection and Immunity 75:
5191–5199.
41. Raffatellu M, Wilson RP, Chessa D, Andrews-Polymenis H, Tran QT, et al.
(2005) SipA, SopA, SopB, SopD, and SopE2 contribute to Salmonella enterica serotype
Typhimurium invasion of epithelial cells. Infection and Immunity 73: 146–154.
42. Baumler AJ, Tsolis RM, Valentine PJ, Ficht TA, Heffron F (1997) Synergistic
effect of mutations in invA and lpfC on the ability of Salmonella Typhimurium to
cause murine typhoid. Infection and Immunity 65: 2254–2259.
43. Morgan E, Campbell JD, Rowe SC, Bispham J, Stevens MP, et al. (2004)
Identification of host-specific colonization factors of Salmonella enterica serovar
Typhimurium. Molecular Microbiology 54: 994–1010.
44. Watson PR, Paulin SM, Bland AP, Jones PW, Wallis TS (1995) Characteriza-
tion of intestinal invasion by Salmonella Typhimurium and Salmonella Dublin and
effect of a mutation in the InvH gene. Infection and Immunity 63: 2743–2754.
45. Wallis TS, Galyov EE (2000) Molecular basis of Salmonella-induced enteritis.
Molecular Microbiology 36: 997–1005.
46. Tenor JL, McCormick BA, Ausubel FM, Aballay A (2004) Caenorhabditis elegans-
based screen identifies Salmonella virulence factors required for conserved host-
pathogen interactions. Current Biology 14: 1018–1024.
47. Murray RA, Lee CA (2000) Invasion genes are not required for Salmonella enterica
serovar Typhimurium to breach the intestinal epithelium: Evidence that
Salmonella Pathogenicity Island 1 has alternative functions during infection.
Infection and Immunity 68: 5050–5055.
48. Coombes BK, Coburn BA, Potter AA, Gomis S, Mirakhur K, et al. (2005)
Analysis of the contribution of Salmonella Pathogenicity Islands 1 and 2 to enteric
disease progression using a novel bovine heal loop model and a murine model of
infectious enterocolitis. Infection and Immunity 73: 7161–7169.
49. Hu QH, Coburn B, Deng WY, Li YL, Shi XL, et al. (2008) Salmonella enterica
serovar Senftenberg human clinical isolates lacking SPI-1. Journal of Clinical
Microbiology 46: 1330–1336.
50. Desin TS, Lam PKS, Koch B, Mickael C, Berberov E, et al. (2009) Salmonella
enterica serovar Enteritidis Pathogenicity Island 1 is not essential for but facilitates
rapid systemic spread in chickens. Infection and Immunity 77: 2866–2875.
51. Jeong JH, Song M, Park SI, Cho KO, Rhee JH, et al. (2008) Salmonella enterica
serovar Gallinarum requires ppGpp for internalization and survival in animal
cells. Journal of Bacteriology 190: 6340–6350.
52. Martinez-Argudo I, Jepson MA (2008) Salmonella translocates across an in vitro M
cell model independently of SPI-1 and SPI-2. Microbiology-SGM 154:
3887–3894.
53. Kehrer JP, Biswal SS (2000) The molecular effects of acrolein. Toxicological
Sciences 57: 6–15.
54. O’Brien PJ, Siraki AG, Shangari N (2005) Aldehyde sources, metabolism,
molecular toxicity mechanisms, and possible effects on human health. Critical
Reviews in Toxicology 35: 609–662.
55. Weizman Z, Alsheikh A (2006) Safety and tolerance of a probiotic formula in
early infancy comparing two probiotic agents: A pilot study. Journal of the
American College of Nutrition 25: 415–419.
56. Wolf BW, Garleb KA, Ataya DG, Casas IA (1995) Safety and tolerance of
Lactobacillus reuteri in healthy adult male subjects. Microbial Ecology in Health
and Disease 8: 41–50.
57. Rosander A, Connolly E, Roos S (2008) Removal of antibiotic resistance gene-
carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of
the resulting daughter strain, L. reuteri DSM 17938. Applied and Environmental
Microbiology 74: 6032–6040.
58. Wolf BW, Wheeler KB, Ataya DG, Garleb KA (1998) Safety and tolerance of
Lactobacillus reuteri supplementation to a population infected with the Human
Immunodeficiency Virus. Food and Chemical Toxicology 36: 1085–1094.
59. Johansson MEV, Phillipson M, Petersson J, Velcich A, Holm L, et al. (2008) The
inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of
bacteria. Proceedings of the National Academy of Sciences of the United States
of America 105: 15064–15069.
60. Johansson MEV, Larsson JMH, Hansson GC (2011) The two mucus layers of
colon are organized by the MUC2 mucin, whereas the outer layer is a legislator
of host-microbial interactions. Proceedings of the National Academy of Sciences
of the United States of America 108: 4659–4665.
61. Becker D, Selbach M, Rollenhagen C, Ballmaier M, Meyer TF, et al. (2006)
Robust Salmonella metabolism limits possibilities for new antimicrobials. Nature
440: 303–307.
62. Bobik TA, Xu YP, Jeter RM, Otto KE, Roth JR (1997) Propanediol utilization
genes (pdu) of Salmonella Typhimurium: Three genes for the propanediol
dehydratase. Journal of Bacteriology 179: 6633–6639.
63. Thiennimitr P, Winter SE, Ba¨umler AJ (2011) Salmonella, the host and its
microbiota. Current Opinion in Microbiology 15: 108–114.
64. Payne AN, Zihler A, Chassard C, Lacroix C (2012) Advances and perspectives
in in vitro human gut fermentation modeling. Trends in Biotechnology 30: 17–25.
65. Gulig PA, Curtiss R (1987) Plasmid-associated virulence of Salmonella
Typhimurium Infection and Immunity 55: 2891–2901.
66. Boyer HW, Roulland-Dussoix D (1969) A complementation analysis of the
restriction and modification of DNA in Escherichia coli. Journal of Molecular
Biology 41: 459–472.
Reuterin Protects against S. Typhimurium Infection
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e37116
